TeGenero AG's TGN 1412 Phase 1 Trial Goes Wrong In UK, Two Critically Ill
LONDON, March 15 (Reuters) - Two men were critically ill in a British hospital on Wednesday and four others serious in intensive care after suffering violent reactions to TeGenero AG's new drug (TGN 1412) they took as part of a clinical trial conducted by Parexel International Corp. Police said they were working with the country's medicines watchdog to establish the circumstances.